Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ ...

Proficio Capital Partners LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the fourth ...

Devices (MASS) stock soars 71% premarket as Repligen (RGEN) announces $70M acquisition of its bioprocessing analytics portfolio. Read more here.

Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN – Get Free Report) in a report ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...